[Comment] Pimavanserin for patients with Alzheimer's disease psychosis

Pimavanserin is an atypical antipsychotic marketed in the USA for hallucinations and delusions associated with Parkinson's disease.1 It acts as an inverse agonist at the 5-HT2A receptor with no effect on dopamine receptors. A boxed warning on the prescribing information approved by the US Food and Drug Administration states that pimavanserin is not approved for elderly patients with dementia-related psychosis unrelated to Parkinson's disease psychosis, and that these patients are at increased risk of death when treated with antipsychotics.

Source: Lancet Neurology - February 14, 2018 Category: Neurology Authors: Lon S Schneider Tags: Comment Source Type: research